226 related articles for article (PubMed ID: 34817189)
1. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI.
Gan JM; Kikano EG; Smith DA; Rao S; Podury R; Wang M; Durieux JC; Paspulati RM; Ponsky L; Ramaiya NH; Tirumani SH
AJR Am J Roentgenol; 2022 May; 218(5):859-866. PubMed ID: 34817189
[No Abstract] [Full Text] [Related]
2. Values of multiparametric and biparametric MRI in diagnosing clinically significant prostate cancer: a multivariate analysis.
Feng X; Chen X; Peng P; Zhou H; Hong Y; Zhu C; Lu L; Xie S; Zhang S; Long L
BMC Urol; 2024 Feb; 24(1):40. PubMed ID: 38365673
[TBL] [Abstract][Full Text] [Related]
3. Avoiding Unnecessary Biopsy after Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study.
Singh S; Rogers H; Kanber B; Clemente J; Pye H; Johnston EW; Parry T; Grey A; Dinneen E; Shaw G; Heavey S; Stopka-Farooqui U; Haider A; Freeman A; Giganti F; Atkinson D; Moore CM; Whitaker HC; Alexander DC; Panagiotaki E; Punwani S
Radiology; 2022 Dec; 305(3):623-630. PubMed ID: 35916679
[TBL] [Abstract][Full Text] [Related]
4. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
[TBL] [Abstract][Full Text] [Related]
5. Risk factor analysis and optimal cutoff value selection of PSAD for diagnosing clinically significant prostate cancer in patients with negative mpMRI: results from a high-volume center in Southeast China.
Lin S; Jiang W; Ding J; Hao S; Chen H; Xie L; Zheng X
World J Surg Oncol; 2024 May; 22(1):140. PubMed ID: 38802859
[TBL] [Abstract][Full Text] [Related]
6. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
Pellegrino F; Stabile A; Sorce G; Quarta L; Robesti D; Cannoletta D; Cirulli G; Barletta F; Scuderi S; Mazzone E; de Angelis M; Brembilla G; De Cobelli F; Salonia A; Montorsi F; Briganti A; Gandaglia G
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37865591
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.
Wang S; Kozarek J; Russell R; Drescher M; Khan A; Kundra V; Barry KH; Naslund M; Siddiqui MM
Eur Urol Oncol; 2024 Apr; 7(2):189-203. PubMed ID: 37640584
[TBL] [Abstract][Full Text] [Related]
8. Benefit of dynamic contrast-enhanced (DCE) imaging for prostate cancer detection depending on readers experience in prostate MRI.
Ziayee F; Schimmöller L; Boschheidgen M; Kasprowski L; Al-Monajjed R; Quentin M; Radtke JP; Albers P; Antoch G; Ullrich T
Clin Radiol; 2024 Mar; 79(3):e468-e474. PubMed ID: 38185579
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies.
Wang Y; Wang L; Tang X; Zhang Y; Zhang N; Zhi B; Niu X
BMC Med Imaging; 2023 Aug; 23(1):106. PubMed ID: 37582697
[TBL] [Abstract][Full Text] [Related]
10. The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting.
Hansen NL; Barrett T; Koo B; Doble A; Gnanapragasam V; Warren A; Kastner C; Bratt O
BJU Int; 2017 May; 119(5):724-730. PubMed ID: 27488931
[TBL] [Abstract][Full Text] [Related]
11. Utilization trend of prebiopsy multiparametric magnetic resonance imaging and its impact on prostate cancer detection: Real-world insights from a high-volume center in southwest China.
Zhang C; Tu X; Dai J; Zhang Z; Shen C; Wu Q; Liu Z; Lin T; Qiu S; Yang L; Yang L; Zhang M; Cai D; Bao Y; Zeng H; Wei Q
Prostate; 2024 May; 84(6):539-548. PubMed ID: 38173301
[TBL] [Abstract][Full Text] [Related]
12. Optimal PSA density threshold and predictive factors for the detection of clinically significant prostate cancer in patient with a PI-RADS 3 lesion on MRI.
Nguyen TA; Fourcade A; Zambon A; Saout K; Deruelle C; Joulin V; Tissot V; Doucet L; Rozet F; Fournier G; Valeri A
Urol Oncol; 2023 Aug; 41(8):354.e11-354.e18. PubMed ID: 37391283
[TBL] [Abstract][Full Text] [Related]
13. Radiologists' Contribution to Variation in Detecting Clinically Significant Prostate Cancer in Men With Prostate MRI.
Naik S; Burk KS; Budiawan E; Lacson R; Lee LK; Fennessy FM; Tempany C; Cole AP; Trinh QD; Kibel AS; Khorasani R
J Am Coll Radiol; 2022 Dec; 19(12):1312-1321. PubMed ID: 36244674
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for prostate cancer in men with false-negative mpMRI: A retrospective single center cohort study of image quality scores and clinical parameters.
Pausch AM; Ghafoor S; Kluckert J; Rupp NJ; Eberli D; Hötker AM
Eur J Radiol; 2024 Jan; 170():111227. PubMed ID: 38039782
[TBL] [Abstract][Full Text] [Related]
15. The effect of the combination of prostate-specific antigen derivatives with multiparametric prostate magnetic resonance imaging scores on the negative predictive value of it in grey zone patients.
Bostancı C; Demir DÖ
Actas Urol Esp (Engl Ed); 2024 Apr; 48(3):238-245. PubMed ID: 37838326
[TBL] [Abstract][Full Text] [Related]
16. Risk-Adapted Strategy Combining Magnetic Resonance Imaging and Prostate-Specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 ``Gray Zone'' Lesions.
Akpinar C; Oz DK; Oktar A; Suer E; Ozden E; Haliloglu N; Gulpinar O; Gokce MI; Gogus C; Baltaci S
Clin Genitourin Cancer; 2024 Jun; 22(3):102071. PubMed ID: 38555682
[TBL] [Abstract][Full Text] [Related]
17. Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer.
Pellegrino F; Stabile A; Sorce G; Mazzone E; Cannoletta D; Cirulli GO; Quarta L; Leni R; Robesti D; Brembilla G; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Prostate; 2024 Apr; 84(5):473-478. PubMed ID: 38149793
[TBL] [Abstract][Full Text] [Related]
18. Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center.
Krausewitz P; Büttner T; von Danwitz M; Weiten R; Cox A; Klümper N; Stein J; Luetkens J; Kristiansen G; Ritter M; Ellinger J
BMC Urol; 2024 Mar; 24(1):71. PubMed ID: 38532370
[TBL] [Abstract][Full Text] [Related]
19. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
Fang AM; Shumaker LA; Martin KD; Jackson JC; Fan RE; Khajir G; Patel HD; Soodana-Prakash N; Vourganti S; Filson CP; Sonn GA; Sprenkle PC; Gupta GN; Punnen S; Rais-Bahrami S
Cancer; 2022 Sep; 128(18):3287-3296. PubMed ID: 35819253
[TBL] [Abstract][Full Text] [Related]
20. Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy.
Busetto GM; Del Giudice F; Maggi M; De Marco F; Porreca A; Sperduti I; Magliocca FM; Salciccia S; Chung BI; De Berardinis E; Sciarra A
World J Urol; 2021 Jun; 39(6):1869-1877. PubMed ID: 32681273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
